Trexquant Investment’s Takeda Pharmaceutical TAK Stock Holding History

Trexquant Investment’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-229,460	Closed	-$4.25M	–	2225
2026 Q1	$4.25M	Buy	+229,460	New	+$4.03M	0.03%	715
2023 Q2	–	Sell	-147,340	Closed	-$2.43M	–	1798
2023 Q1	$2.43M	Sell	147,340 -20,168	-12%	-$321K	0.07%	393
2022 Q4	$2.61M	Buy	167,508 +154,122	+1,151%	+$2.15M	0.07%	341
2022 Q3	$174K	Sell	13,386 -33,887	-72%	-$471K	0.01%	1221
2022 Q2	$664K	Buy	+47,273	New	+$675K	0.03%	685
2022 Q1	–	Sell	-33,525	Closed	-$457K	–	1716
2021 Q4	$457K	Buy	+33,525	New	+$470K	0.03%	693
2020 Q3	–	Sell	-15,076	Closed	-$270K	–	1525
2020 Q2	$270K	Buy	+15,076	New	+$271K	0.02%	930
2020 Q1	–	Sell	-11,243	Closed	-$222K	–	1410
2019 Q4	$222K	Buy	11,243 +589	+6%	+$11.3K	0.01%	873
2019 Q3	$183K	Buy	+10,654	New	+$184K	0.02%	767

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Trexquant Investment's TAK Position: Q2 2026 in Review

Trexquant Investment sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 229,460 shares — an estimated $4.25M sold.

Trexquant Investment first reported a position in TAK in Q3 2019 and held it in 9 quarters. The position peaked at $4.25M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Trexquant Investment reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Trexquant Investment sold 229,460 Takeda Pharmaceutical shares in Q2 2026, an estimated $4.25M.
Trexquant Investment first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 9 quarters.
Trexquant Investment's Takeda Pharmaceutical position peaked at $4.25M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.